Navigation Links
Vasogen Announces Sale of Patent Application and Provides Corporate Update
Date:2/2/2009

hould not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings, including our Management's Discussion and Analysis for the quarter ended August 31, 2008. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
2. Vasogen Provides Corporate Update
3. Vasogen Announces Third Quarter 2008 Results
4. Vasogen Announces Second Quarter 2008 Results
5. Vasogen Provides Corporate Update
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
8. Vasogen Announces Implementation of Strategic Restructuring Plan
9. Vasogen Announces First Quarter 2008 Results
10. Vasogen to Webcast its Annual Meeting
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... ... 2015 , ... The new Xsample 530 sample changer for vials can be used ... viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) – ... catches the eye about Xsample 530 is its removable magazine, which is easily lifted off ...
(Date:7/28/2015)... ... 28, 2015 , ... In terms of value, aluminium hydroxide ... volume reached close to 1.84 million tonnes in the same year. As of ... the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted a ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... the Deerfield Healthcare Innovations Fund, L.P., which will invest ... therapeutic interventions in genetic diseases, cancer, and orphan diseases. ... that can transform how therapeutics are developed and improve ... The fund, one of the largest healthcare-focused venture funds ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... , , FT. LAUDERDALE, ... Bulletin Board: ISPI) announced today an important development within the ... technology of Integral Bioenergies Systems, SL (IBS). This firm has ... treatment of biomass/sludge obtained at sewage treatment plants. , IBS ...
... Feb. 5 Novavax, Inc. (Nasdaq: NVAX ) a ... and Chief Executive Officer of Novavax will be presenting at the 12th ... at 10:00 am local time. Hosted by the Biotechnology Industry ... place February 8-9 at the Waldorf = Astoria, New ...
... , LONDON and PALO ALTO, Calif. ... plc (AIM: SLN) today announced that Philip Haworth , Ph.D., chief ... 12th Annual BIO CEO & Investor Conference.  The conference will be held ... York City . , Silence,s presentation will take place at 11:00 ...
Cached Biology Technology:InfoSpi Shall Benefit From Contract for Future Use of IBS Technology 2NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 3
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 2010) Internationally renowned chemical biologist Dr. Carolyn ... biopharmaceutical industry, has achieved extraordinary success for her ... proven potential for future advances, and her current ... their surfaces and secreted proteins, have won Bertozzi ...
... gene that makes humans more susceptible to the potentially fatal ... virus affecting horses, according to scientists at the University ... the OAS1 gene has now been confirmed as increasing the ... a study led by Professor David Adelson (University ...
... 2010 Scientists have developed a new massively-parallel approach ... their interactions under force. The finding appears in the ... The team of researchers from the Rowland Institute at ... "single molecule centrifugation", offers dramatic improvements in throughput and ...
Cached Biology News:Chemical biologist and entrepreneur Carolyn Bertozzi awarded $500,000 Lemelson-MIT Prize 2Chemical biologist and entrepreneur Carolyn Bertozzi awarded $500,000 Lemelson-MIT Prize 3Mutant gene link to West Nile virus in horses 2Single-molecule manipulation for the masses 2
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Request Info...
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: